Sector News

Takeda taps Elektrofi’s microparticle delivery platform for potential subq plasma offerings

September 30, 2020
Life sciences

Takeda has joined forces with drug delivery specialist Elektrofi to see whether the biotech’s microparticle formulation technology could enable simpler dosing with plasma-derived therapies.

Takeda will assess Elektrofi’s drug delivery platform using an undisclosed plasma protein, with the long-term aim of creating and testing high-concentration, low-viscosity samples, Elektrofi said in a release.

Elektrofi’s microparticle formulations might eventually allow plasma therapies to be injected into the skin rather than infused via IV. And that, in turn, could help bolster the Japanese drugmaker’s plasma portfolio by improving patients’ experience with the products, a Takeda spokeswoman said via email.

Meanwhile, providing simpler, under-the-skin dosing options for monoclonal antibodies, plasma therapies and other biologic drugs fits lockstep with Elektrofi’s greater mission to ease the treatment burden on patients as well as hospitals, co-founder and CEO Chase Coffman, Ph.D., told Fierce Pharma.

“With Elektrofi’s technology, these medicines can be reformulated for subcutaneous administration, which provides substantial convenience and cost-benefit to patients,” Coffman said. The subcutaneous route is often safer than IV administration and may curb the risk of side effects, too, he added.

Elektrofi’s patented technology is used to engineer ultra-high concentration, low-viscosity protein formulations that can be administered as low-volume, subcutaneous injections. The formulations can even be administered using commercially available devices like autoinjectors, which could transform IV drugs into products easy to use at home.

Takeda will kick off the Elektrofi arrangement by testing the storage stability of Elektrofi’s microparticle formulations—another potential strength of the delivery specialist’s platform, Coffman thinks. The proteins in Elektrofi’s micoparticle formulations are dehydrated, which improves shelf life and thermal durability compared with conventional aqueous formulations, Coffman said.

For Takeda’s part, the drugmaker has made plasma a focus of late, including multiple plasma-based efforts against the COVID-19 pandemic.

The company early this year forged a partnership with a range of plasma specialists—including CSL Behring, Biotest, LFB and Octapharma—hoping to quickly roll out an effective coronavirus treatment. That effort, dubbed the CoVIg-19 Plasma Alliance, has since won the support of ADMA Biologics, BioPharma Plasma and Liminal BioScience, among others.

And, in early March, Takeda kicked off development of its own plasma-derived therapy against the novel coronavirus, dubbed TAK-888. That candidate is now set to enter a late-stage trial this month, Reuters reported, after a planned start in July hit a snag.

Meanwhile, the Takeda deal follows another major drug delivery win for Elektrofi this summer. The biotech in August forged a pact with Danish drugmaker LEO Pharma to pair its drug delivery platform with LEO antibodies for a specific, undisclosed dermatology indication.

The companies are developing a subcutaneous skin drug using Elektrofi’s delivery platform, with Elektrofi teed up to receive an undisclosed cash sum plus milestone payments and potential sales royalties from the deal.

By: Fraiser Kansteiner

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach